In its most recent SEC filing for the third quarter, Hantz Financial Services Inc. increased its holding in Novartis AG by 53.8%, acquiring an additional 14,342 shares to bring its total position to 40,980 shares. At the time of the filing, this stake was valued at approximately $5.255 million. This strategic move by Hantz marks it as one of the largest incremental buyers of Novartis stock during the quarter, reflecting growing institutional confidence ahead of the company’s year-end results.

Novartis reported fourth-quarter net sales of $13.34 billion, representing a 1% year-over-year increase but falling short of consensus estimates of $13.78 billion. On a constant-currency basis, sales declined by 1%, primarily due to generic competition impacting flagship products Entresto and Promacta. Adjusted earnings per share came in at $2.03, topping the analyst consensus of $1.99. Core operating income rose 1% to $4.93 billion, driven by lower SG&A expenses and higher government grant income, offsetting increased R&D investments. Growth in oncology and immunology franchises helped offset revenue pressure from legacy products.

For fiscal 2026, management forecasts net sales growth in the low single digits while expecting core operating income to decline by a similar margin. CEO Vas Narasimhan emphasized that operating income momentum should return in the second half of the year, aligning with mid-term guidance targets. The regulatory pipeline remains robust, with Remibrutinib submitted for FDA review, Phase III data expected for Pelabresib in myelofibrosis, recent EU approval for Scemblix in chronic myeloid leukemia, and filings planned for Pluvicto in prostate cancer. These milestones, combined with sustained analyst Buy ratings, support a constructive long-term thesis despite near-term patent expiry pressures.